Hans Wandall

Company: GO Therapeutics

Job title: Chief Scientific Officer

Seminars:

Advancing Next-Gen ADCs that Target Novel Cancer-Specific Glyco-Targets 9:10 am

Introducing the O-glycoproteome platform, to expand the druggable target space beyond the proteome Discussing how mAbs that recognize clean glycopeptide epitopes mitigate on-target, off-tumor toxicities for higher therapeutic index Evidencing ADCs built on glycopeptide-targeting mAbs are less prone to resistance via target down-regulation, and clean tumor selectivity supports the use of more potent payloadsRead more

day: Conference Day Two